Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

Leila Mahdavi, Haley Goodrow, Hongbo Xie, Alexandra Lenard, Fatemeh Alikarami, Simone Stefanie Riedel, Sarah K. Tasian, Gerald Wertheim, Sarah Skuli, Martin Carroll, Jerry McGeehan, Kathrin M. Bernt

Blood (2023) 142 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2023-180967

Published: 2023

Journal Articles

Somatic Mutation Screening in Adult Patients with Myeloid Malignancies Provides Insights into Likely Germline Variants

Rahul S. Bhansali, Xin Wang, Valentina Mattfeld, Dana F. Clark, Jennifer JD Morrissette, Martin Carroll, Daria Babushok, Ximena Jordan Bruno

Blood (2023) 142 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2023-174488

Published: 2023

Journal Articles

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Brian Chernak, Marta Galan-Diez, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Ziwei Chen, Thomas Koehnke, Ravindra Majeti, Martin Carroll, Azra Raza, Stavroula Kousteni

Blood (2023) 142 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2023-174485

Published: 2023

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Blood (2023) 142 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2023-186514

Published: 2023

Journal Articles

NAMPT Haploinsufficiency Is a Therapeutic Vulnerability in High-Risk Myeloid Malignancies

Madhavi D. Senagolage, Saira Khan, Sarah Skuli, Martin Carroll, Megan E. McNerney

Blood (2023) 142 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2023-191061

Published: 2023

Journal Articles

The Mevalonate Pathway Is a Therapeutic Target in TP53 Mutant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 408.

https://doi.org/10.1182/blood-2023-185059

Published: 2023

Journal Articles

Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging

Blood (2023) 142 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2023-179280

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Loss of CCAAT‐Enhancer Binding Protein Delta Promotes Acute Myeloid Leukemia Cell Proliferation and Survival By Upregulating Cyclin D1 Expression

Blood (2023) 142 (Supplement 1): 1380.

https://doi.org/10.1182/blood-2023-181946

Published: 2023

Journal Articles

Developing a Humanized Murine Model for Co-Transplantation of Acute Myeloid Leukemia

Ding-Wen Chen, Tingting Huang, Yuyang Huang, Stephanie N Hurwitz, Julie Schrey, Jian-Meng Fan, Martin Carroll, Peter Kurre, Bonnie W Lau

Blood (2022) 140 (Supplement 1): 5776–5777.

https://doi.org/10.1182/blood-2022-158615

Published: 2022

Journal Articles

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

Caroline Duault, Anil Kumar, Adeleh Taghi Khani, Sung June Lee, Lu Yang, Min Huang, Christian Hurtz, Bryan Manning, Lucy Ghoda, Tinisha McDonald, Norman J. Lacayo, Kathleen M. Sakamoto, Martin Carroll, Sarah K. Tasian, Guido Marcucci, Jianhua Yu, Michael A. Caligiuri, Holden T. Maecker, Srividya Swaminathan

Blood (2021) 138 (16): 1465–1480.

https://doi.org/10.1182/blood.2020009871

Published: 2021

Includes: Supplemental data

Journal Articles

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Kimihito C. Kawabata, Hongliang Zong, Cem Meydan, Sarah Wyman, Bas J. Wouters, Mayumi Sugita, Srinjoy Goswami, Michael Albert, Winnie Yip, Gail J. Roboz, Zhengming Chen, Ruud Delwel, Martin Carroll, Christopher E. Mason, Ari Melnick, Monica L. Guzman

Blood (2021) 137 (6): 812–825.

https://doi.org/10.1182/blood.2019001745

Published: 2021

Includes: Supplemental data

Journal Articles

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

Blood (2020) 136 (6): 698–714.

https://doi.org/10.1182/blood.2019003062

Published: 2020

Includes: Supplemental data

Journal Articles

A common protein target for an uncommon subtype of AML

Martin Carroll

Blood (2020) 136 (4): 377–378.

https://doi.org/10.1182/blood.2020006487

Published: 2020

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response

Dennis J. Eastburn, PhD, Christine M. McMahon, MD, Robert Durruthy-Durruthy, PhD, Martin Carroll, MD, Catherine C. Smith, MD, Alexander E. Perl, MD

Blood (2018) 132 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2018-99-119869

Published: 2018

Journal Articles

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

Miguel Torres Martin, PhD, Grace Jeschke, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Maria E. Figueroa, MD

Blood (2017) 130 (Supplement 1): 3922.

https://doi.org/10.1182/blood.V130.Suppl_1.3922.3922

Published: 2017

NARROW

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

Somatic Mutation Screening in Adult Patients with Myeloid Malignancies Provides Insights into Likely Germline Variants

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

NAMPT Haploinsufficiency Is a Therapeutic Vulnerability in High-Risk Myeloid Malignancies

The Mevalonate Pathway Is a Therapeutic Target in TP53 Mutant Acute Myeloid Leukemia

Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic Imaging

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Loss of CCAAT‐Enhancer Binding Protein Delta Promotes Acute Myeloid Leukemia Cell Proliferation and Survival By Upregulating Cyclin D1 Expression

Developing a Humanized Murine Model for Co-Transplantation of Acute Myeloid Leukemia

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

A common protein target for an uncommon subtype of AML

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only